Association of AKT1 gene polymorphisms with therapeutic effects of 8-week treatment with risperidone
10.3969/j.issn.1000-6729.2018.02.007
- VernacularTitle:AKT1基因多态性与利培酮治疗精神分裂症8周疗效的关联研究
- Author:
Xiaojun LI
1
;
Tianlan LU
;
Weihua YUE
;
Dai ZHANG
Author Information
1. 北京大学第六医院
- Keywords:
schizophrenia;
AKT1;
polymorphisms;
risperidone;
therapeutic effects
- From:Chinese Mental Health Journal
2018;32(2):125-129
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the association of AKT1 gene polymorphism with risperidone in the treatment of first-episode and untreated schizophrenia for 8 weeks.Methods:A total of 150 patients with Chinese schizophrenia who met DSM-Ⅳ,including 128 cases of risperidone (treatment dose 4-6 mg/d) for 8 weeks were treated with risperidone (treatment dose 4-6 mg/d).The Positive and Negative Symptom Scale (PANSS) reduction rate was used to evaluate the curative effect of drugs after 8 weeks.Using DNA sequencing,four single nucleotide polymorphisms (SNP) loci (rs1130214,rs10149779,rs1130233,rs2494732) genotype were detected in 128 Han patients with schizophrenia,and quantitative trait locus analysis (QTL) was used to explore the association between AKT1 gene polymorphisms and the efficacy of risperidone in the treatment of schizophrenia.Results:AKT1 gene rs1130233 (G ＞ A) and rs2494732(C ＞ T) were significantly associated with the increase in PANSS after 8-week risperidone treatment of schizophrenia (P ＜ 0.05).After repeated testing Bonferroni correction was still statistically significant.The correlation between rs1130214and rs10149779 in this sample was not statistically significant (P ＞0.05).Conclusion:This study suggests that polymorphisms of the AKT1 gene may be associated with the efficacy of risperidone in the treatment of schizophrenia in the Chinese Han population and is expected to provide a basis for the prediction of individual drug efficacy.
